All Photos(1)
Synonym(s):
AC1LOE9L, CID-1261822, CID1261822, N-{4-[(3,4-Dimethyl-1,2-oxazol-5-yl)sulfamoyl]phenyl}-6,8-dimethyl-2-(pyridin-2-yl)quinoline-4-carboxamide trifluoroacetate
Empirical Formula (Hill Notation):
C28H25N5O4S · C2HF3O2
CAS Number:
Molecular Weight:
641.62
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
Recommended Products
Quality Level
Assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 25 mg/mL, clear
storage temp.
2-8°C
SMILES string
FC(F)(C(O)=O)F.CC1=C(ON=C1C)NS(C2=CC=C(NC(C3=CC(C4=CC=CC=N4)=NC5=C3C=C(C)C=C5C)=O)C=C2)(=O)=O
Biochem/physiol Actions
ML193 is a potent and selective piperadinyloxadiazolone antagonist for G protein-coupled receptor (GPCR) GPR55, a receptor for L-α-lysophosphatidylinositol (LPI) which also binds synthetic cannabinoids, and signals through several endogenous pathways. GPR55 is highly abundant in the CNS as well as in intestine, bone marrow, spleen, platelets, immune and endothelial cells. Its role is not completely understood, but has been implicated in inflammatory pain, neuropathic pain, metabolic disorder, bone development, and cancer. Selective antagonists are needed to further elucidate the role of GPR55 in physiology and pathobiology. ML193 (CID1261822) has 221 nM potency for GPR55 and >145-fold, >27-fold and >145-fold antagonist selectivity against GPR35, cannabinoid receptors CB1 and CB2, respectively and >145-fold agonist selectivity against GPR35, CB1 and CB2. ML193 is inhibits the downstream responses of ERK phosphorylation with an IC50 of 65 nM and PKC βII translocation with an IC50 of 10 μM.
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Evangelia Kotsikorou et al.
Biochemistry, 52(52), 9456-9469 (2013-11-28)
GPR55 is a class A G protein-coupled receptor (GPCR) that has been implicated in inflammatory pain, neuropathic pain, metabolic disorder, bone development, and cancer. Initially deorphanized as a cannabinoid receptor, GPR55 has been shown to be activated by non-cannabinoid ligands
Justine Yu et al.
The Journal of biological chemistry, 288(31), 22481-22492 (2013-07-03)
The L-α-lysophosphatidylinositol (LPI)-sensitive receptor GPR55 is coupled to Ca(2+) signaling. Low levels of GPR55 expression in the heart have been reported. Similar to other G protein-coupled receptors involved in cardiac function, GPR55 may be expressed both at the sarcolemma and
Sandra Cecconi et al.
International journal of molecular sciences, 20(12) (2019-06-20)
Endocannabinoids are key-players of female fertility and potential biomarkers of reproductive dysfunctions. Here, we investigated localization and expression of cannabinoid receptor type-1 and -2 (CB1R and CB2R), G-protein coupled receptor 55 (GPR55), and transient receptor potential vanilloid type 1 channel
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service